CTSO
Cytosorbents Corp
$0.37
-0.02 (-5.12%)
At close · Jul 16
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These cash and restricted cash balances considered with our historical and expected future cash used in operations, notwithstanding our Strategic Workforce and Cost Reduction Plan and the impact of the Amended Loan and Security Agreement, raises substantial doubt about the Company's ability to continue as a going concern within twelve months after the date that the accompanying condensed consolidated financial statements are issued.”View the 10-Q filed May 13, 2026
Market Cap
$22.61M
Shares
62,794,748
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.37
Open$0.38
Day$0.36–0.39
52W$0.35–1.22
Avg vol 30d228K
Short int2.1M · 3.3% float · 6.2d
Short vol80%
Last earningsMay 13, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 13
Up next
Next earnings call
Aug 12, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−43%
below
Price vs 50-day avg
−20%
below
RSI (14)
41
neutral
MACD trend
Positive
52-week position
2%
near low
Momentum
relative strength
1-month return
−29%
trailing
6-month return
−45%
trailing
YTD return
−42%
this year
Relative strength
−54%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Flat
2 of 50 funds reported for Jun 30 · net 0 sh shares
Insider flow
Accumulating
Net +$148.9K over 90 days · 0% sells
Short interest
Falling
3.31% of float · ▼ -0.4% MoM · 6.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
50 holders — mid 3-yr range
Squeeze score
53
elevated · 0–100
Fundamentals
Revenue growth
+49%
Y/Y
Gross margin
118%
contracting
EPS growth
+66%
Y/Y
Free cash flow
$-12.5M
Balance sheet
$12.9M
net debt
Quant / Vol
risk profile
Volatility
82%
annualized · 1-yr
Max drawdown
−70%
past year
ATR
13.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−43%
Bearish
Price vs 50-day avg
−20%
Bearish
RSI (14)
41
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Flat
2 of 50 funds reported for Jun 30 · net 0 sh shares
Insider flow
Accumulating
Net +$148.9K over 90 days · 0% sells
Short interest
Falling
3.31% of float · ▼ -0.4% MoM · 6.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
50 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 2%
52-wk high $1
vs 200-day avg -43%
vs 50-day avg -20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA loss non-GAAP | -$2.2M | Q1 2026 | — |
|
|
|||
| Adjusted net loss non-GAAP | -$3.4M | Q1 2026 | — |
|
|
|||
| Adjusted net loss per share non-GAAP | -$0.05 | Q1 2026 | — |
| Total cash burn, excluding restructuring-related payments | $1.1M | Q1 2026 | — |
| core product sales | $37M | FY2025 call | — |
| countries with devices used | 70 | cumulative through 2025 call | — |
| devices used cumulatively | 300,000 | cumulative through 2025 call | — |
| Direct International sales growth (ex-Germany) | 13% | Q1 FY2026 call | — |
| PuriFi pumps placed internationally | 100 | cumulative to date call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTSO
this stock
Cytosorbents Corp
|
$22.61M | -42.3% | +48.5% | — | 3.3% |
|
ABT
Abbott Laboratories
|
$173.73B | -20.7% | +5.7% | 27.9 | 1.3% |
|
SYK
Stryker Corp
|
$126.97B | -5.5% | +11.2% | 38.3 | 1.8% |
|
MDT
Medtronic plc
|
$106.96B | -12.3% | +8.4% | 22.4 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.32B | -53.2% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTSO | -0.8% | -28.9% | -45.4% | -1.3% | -42.3% |
| SPY | -0.1% | +0.1% | +9.0% | +0.5% | +10.1% |
| vs SPY | -0.7% | -29.0% | -54.4% | -1.9% | -52.3% |